16 Drugs Added to Knowledgebase

We just added 16 new drugs to the knowledgebase:

• BI 1015550 a phosphodiesterase 4B (PDE4B) inhibitor being developed for the treatment of idiopathic pulmonary fibrosis by Boehringer Ingelheim
• MCO-010 a gene therapy being developed for the treatment of Stargardt macular degeneration and retinitis pigmentosa by Nanoscope Therapeutics
• Blarcamesine a sigma-1 receptor agonist being developed for the treatment of Rett Syndrome, Alzheimer’s disease, Parkinson’s disease dementia and Fragile X Syndrome by Anavex Life Sciences
• Epcoritamab a bispecific antibody being developed for the treatment of relapsed or refractory large B-cell lymphoma by AbbVie and Genmab
• Zilucoplan a C5 inhibitor being developed for the treatment of generalized myasthenia gravis by UCB
• Asundexian a Factor XIa inhibitor being developed for the prevention of non-cardioembolic ischemic stroke and myocardial infarction by Bayer
• EDP-938 a nonfusion replication inhibitor being developed for the treatment of respiratory syncytial virus (RSV) by Enanta Pharmaceuticals
• Moderna’s investigational respiratory syncytial virus (RSV) vaccine
• KSI-301 a VEGF Inhibitor being developed for the treatment of neovascular (wet) age-related macular degeneration, macular edema due to retinal vein occlusion and diabetic macular edema by Kodiak Sciences
• GFB-887 a transient receptor potential canonical-5 (TRPC5) inhibitor being developed for the treatment of focal segmental glomerulosclerosis (FSGS), diabetic nephropathy by Goldfinch Bio
• CP101 a microbiome transplant being developed for the prevention of recurrence of C. difficile infection by Finch Therapeutics 
• Ribitol a pentose alcohol being developed for the treatment of limb-girdle muscular dystrophy type 2i (LGMD2i) by BridgeBio Pharma
• Amcenestrant a selective estrogen receptor degrader (SERD) being developed for the treatment of ER+/HER2- advanced or metastatic breast cancer by Sanofi
• Latozinemab an anti-sortilin (SORT1) monoclonal antibody f being developed or the treatment of frontotemporal dementia patients (FTD) with a C9orf72 genetic mutation fro by m Alector and GlaxoSmithKline 
• Imsidolimab an anti-IL-36R monoclonal antibody being developed for the treatment of hidradenitis suppurativa and pustular psoriasis by AnaptysBio
• Iberdomide a cereblon ligand being developed for the treatment of systemic lupus erythematosus by Bristol Myers Squibb​
  

The Prescribe Right Pharmaceutical Pipeline Tracker now allows you to track 1,021 pipeline and recently approved drugs supported by 2,551 announced and published study results.